No Data
No Data
No Data
No Data
No Data
麗珠醫藥:2023年報
Futu NewsApr 29 05:42 ET · Announcements
Livzon Pharmaceuticals (01513.HK): Cetrorelix acetate for injection was approved by the US FDA
On April 26, GLONGHUI Pharmaceutical (01513.HK) issued an announcement. Recently, Lizhu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an ANDA approval notice (ANDA number: 214540) issued by the US Food and Drug Administration (hereinafter referred to as the “US FDA”) to approve the marketing and sale of injectable cetrorelix acetate developed by the company in the US.
Gelonghui FinanceApr 26 05:59 ET
Pearl Pharmaceuticals (01513) spent HK$436,300 to buy back 16,700 shares on April 25
According to the Zhitong Finance App, Lizhu Pharmaceutical (01513) announced that on April 25, 2024, the company spent HK$436,300 to repurchase 16,700 shares at a repurchase price of HK$26-26.15 per share.
Zhitong FinanceApr 25 06:34 ET
Pearl Pharmaceuticals (01513) spent about HK$7.3579 million to buy back 285,800 shares on April 24
Pearl Pharmaceuticals (01513) announced that on April 24, 2024, it cost approximately HK$7.3579 million to repurchase 28...
Zhitong FinanceApr 24 05:48 ET
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%
Livzon Pharmaceutical Group's (HKG:1513, SHE:000513) attributable profit rose 4.45% to 607.8 million yuan in the first quarter from 581.9 million yuan in the year-ago period, according to a Wednesday
MT NewswiresApr 24 03:42 ET
Lizhu Pharmaceutical (01513.HK)'s net profit of 608 million yuan in the first quarter increased 4.45% year-on-year
Gelonghui, April 23 | Lizhu Pharmaceutical (01513.HK) announced that in the first quarter of 2024, the company achieved operating income of 3.243 billion yuan in the first quarter, a year-on-year decrease of 4.99%; net profit to mother was 608 million yuan, up 4.45% year on year; and basic earnings per share were 0.65 yuan.
Gelonghui FinanceApr 23 06:17 ET
No Data
No Data